Literature DB >> 21640496

Definitive radiotherapy for T1-2 hypopharyngeal cancer: a single-institution experience.

Aya Nakajima1, Kinji Nishiyama, Masahiro Morimoto, Satoaki Nakamura, Osamu Suzuki, Yoshifumi Kawaguchi, Ken Miyagi, Takashi Fujii, Kunitoshi Yoshino.   

Abstract

PURPOSE: To analyze the outcome in T1-2 hypopharyngeal cancer (HPC) patients treated with definitive radiotherapy (RT). PATIENTS AND METHODS: A total of 103 patients with T1-2 hypopharyngeal squamous cell carcinoma treated with radical RT between March 2000 and June 2008 at our institution were analyzed. Pre-RT neck dissection (ND) was performed in 26 patients with advanced neck disease. Chemotherapy was used concurrently with RT in 14 patients. Sixty patients were associated with synchronous or metachronous malignancies. The median follow-up for surviving patients was 41 months.
RESULTS: The 3-year overall and cause-specific survival rates were 70% and 79%, respectively. The 3-year local control rates were 87% for T1 and 83% for T2 disease. The ultimate local control rate was 89%, including 7 patients in whom salvage was successful. The ultimate local control rate with laryngeal preservation was 82%. Tumors of the medial wall of the pyriform sinus tended to have lower control rates compared with tumors of the lateral or posterior pharyngeal wall. Among patients with N2b-3 disease, the 3-year regional control rates were 74% for patients with pre-RT ND and 40% for patients without ND. The 3-year locoregional control rates were as follows: Stage I, 100%; Stage II, 84%; Stage III, 67%; Stage IVA, 43%; Stage IVB, 67%. Forty-two patients developed disease recurrence, with 29 (70%) patients developing recurrence within the first year. Of the 103 patients, 6 developed late complications higher than or equal to Grade 3.
CONCLUSIONS: Definitive RT accomplished a satisfactory local control rate and contributed to organ preservation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21640496     DOI: 10.1016/j.ijrobp.2011.03.040

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  When is definitive radiotherapy the preferred treatment for head and neck squamous cell carcinoma?

Authors:  William M Mendenhall; Primož Strojan; Avraham Eisbruch; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-30       Impact factor: 2.503

2.  Primary radiotherapy for squamous cell carcinoma of the pyriform sinus.

Authors:  William M Mendenhall; Robert J Amdur; Christopher G Morris; Jessica Kirwan; Peter T Dziegielewski; John W Werning
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-14       Impact factor: 2.503

3.  Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer.

Authors:  Kumiko Karasawa; Hiroaki Kunogi; Takahisa Hirai; Hidehiro Hoji; Hisako Hirowatari; Hiromi Izawa; Kana Ito; Keisuke Sasai; Tomohisa Furuya; Shuichi Ozawa; Fumihiko Matsumoto; Shin Ito; Shinichi Oba
Journal:  J Radiat Res       Date:  2013-01-07       Impact factor: 2.724

4.  Case of Superficial Cancer Located at the Pharyngoesophageal Junction Which Was Dissected by Endoscopic Laryngopharyngeal Surgery Combined with Endoscopic Submucosal Dissection.

Authors:  Kenro Kawada; Tatsuyuki Kawano; Taro Sugimoto; Kazuya Yamaguchi; Yuudai Kawamura; Toshihiro Matsui; Masafumi Okuda; Taichi Ogo; Yuuichiro Kume; Yutaka Nakajima; Andres Mora; Takuya Okada; Akihiro Hoshino; Yutaka Tokairin; Yasuaki Nakajima; Ryuhei Okada; Yusuke Kiyokawa; Fuminori Nomura; Takahiro Asakage; Ryo Shimoda; Takashi Ito
Journal:  Case Rep Otolaryngol       Date:  2017-01-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.